[ad_1]
Personalized medicine – delivering therapies specifically tailored to the unique physiology of a patient – has been a goal of researchers and physicians for a long time. New research makes it possible to offer personalized treatments to patients with a neurological disease.
Researchers at the Montreal Neurological Institute and Hospital (Neuro) of McGill University and the Ludmer Center for Neuroinformatics and Mental Health have developed what they call a personalized therapeutic treatment. Fingerprint intervention (pTIF). The pTIF predicts the effectiveness of targeting specific biological factors (amyloid deposition / brain tau, inflammation, neuronal functional dysfunction) to control the course of the patient's disease. Their findings were published in the journal Neuroimage June 14, 2018.
Led by the first author of the study, Ybader Iturria-Medina, the researchers used computational brain modeling techniques and artificial intelligence to badyze neurological data. 331 Alzheimer's patients and healthy controls. The data included several modes of positron emission tomography (PET) and magnetic resonance imaging (MRI). From this, Iturria-Medina and her colleagues were able to categorize patients into their TIF subtypes, depending on the potentially most beneficial interventions specific to the factors.
The authors verified that these subtypes were relevant by comparing them to the individual genetic profiles of patients. They found that patients in the same subtype of pTIF had similar gene expression, which means that the mechanism in which the genes affect their physiology is similar. Because drugs to control the progression of the disease should alter gene expression and brain properties at the same time, drugs tailored to the subtypes of pTIF would be much more effective than drugs designed to treat all affected patients. of Alzheimer's disease.
a direct link between brain dynamics, predicted therapeutic responses and molecular and cognitive alterations in patients. By using subtypes of pTIF, drugs can be designed for the unique gene expression profile of a patient and the phenotypic characteristics of the brain, which is a major advance in personalized medicine. It could also improve the effectiveness and reduce the cost of clinical drug trials if it is used as a method of selecting patients.
"In accordance with the principles of personalized medicine, the framework introduced could lead to more effective medical care, decrease the" We will therefore focus on the application of the pTIF to other neurological disorders, in extensively validating the adverse effects and significantly reducing the pharmaceutical / clinical costs badociated with clinical trials, which will speed up the creation-evaluation cycle of new therapeutic agents, "explains Iturria-Medina, and, above all, by putting the badytical tools that are made available to the international community through open access platforms. "
History Source:
Materials Provided by McGill University . Content can be changed for style and length.
Source link
